Skip to content
Contactez-nous: (+33) 1 64 62 10 12
Theradiag
  • Home
  • Company
    • About us
    • Our history
    • A word from our CEO
    • Our management team
    • Board of directors
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics – TRACKER
      • Therapeutic Drug Monitoring of Biologics
        • TDM of Biologics
        • When to perform TDM ?
        • Results interpretation
        • Therapeutic Thresholds
        • Tracker Publications
        • Guidelines
        • Frequently asked questions
      • TRACKER
        • LISA TRACKER
        • I-Tracker
        • i-Track 10
        • Immunotrol Tracker
    • Patient Stratification -PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • SARS-CoV 2 Serology Testing
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
Menu Close

Press Releases

  1. Home>
  2. Press Releases

08/06/2022: Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics

  • Post author:Quentin Massé
  • Post published:8 June 2022
  • Post category:Press Releases

Continue Reading08/06/2022: Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics

31/05/2022: THERADIAG announces the launch of ez-Track1, a Point-of-Care Testing solution for therapeutic drug monitoring

  • Post author:Quentin Massé
  • Post published:31 May 2022
  • Post category:Press Releases

 

Continue Reading31/05/2022: THERADIAG announces the launch of ez-Track1, a Point-of-Care Testing solution for therapeutic drug monitoring

19/05/2022: THERADIAG announces the launch of two new i-Tracker® kits

  • Post author:Quentin Massé
  • Post published:19 May 2022
  • Post category:Press Releases

 

Continue Reading19/05/2022: THERADIAG announces the launch of two new i-Tracker® kits
  • 1
  • 2
  • 3
  • 4
  • …
  • 42
  • Go to the next page

Latest Press Releases

  • 08/06/2022: Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics
    8 June 2022/
    0 Comments
  • 31/05/2022: THERADIAG announces the launch of ez-Track1, a Point-of-Care Testing solution for therapeutic drug monitoring
    31 May 2022/
    0 Comments
  • 19/05/2022: THERADIAG announces the launch of two new i-Tracker® kits
    19 May 2022/
    0 Comments

Events

08 - 10 Jun 2022

URGENCES LE CONGRES

Palais des Congrès
10 - 13 Jun 2022

13th Interrnational Congress on Autoimmunity

Megaron Athens International Conference Centre
No event found!

Next financial Event

No event found!

Useful links

  • Diagnostic
  • Theranostic
  • Events
  • Register to receive our latests news

Contact Information

  • Address:14, Rue Ambroise Croizat, 77183 Croissy Beaubourg, France
  • Phone:+33 1 64 62 10 12
  • Email:info@theradiag.comOpens in your application

Follow Us

Theradiag ©
  • Home
  • Company
    • About us
    • Our history
    • A word from our CEO
    • Our management team
    • Board of directors
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics – TRACKER
      • Therapeutic Drug Monitoring of Biologics
        • TDM of Biologics
        • When to perform TDM ?
        • Results interpretation
        • Therapeutic Thresholds
        • Tracker Publications
        • Guidelines
        • Frequently asked questions
      • TRACKER
        • LISA TRACKER
        • I-Tracker
        • i-Track 10
        • Immunotrol Tracker
    • Patient Stratification -PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • SARS-CoV 2 Serology Testing
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
We use cookies to ensure the best experience on our website. If you continue to use this site, we will assume that you are satisfied.OkNoLearn more